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MICROFLUIDIC DEVICE
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of priority under 35
U.S.C. §120 as a continuation of U.S. patent application Ser.
No. 14/685,480, filed Apr. 13, 2015, and now U.S. Pat. No.
9,234,884, which is a continuation of U.S. patent application
Ser. No. 14/296,199, filed Jun. 4, 2014, and issued as U.S.
Pat. No. 9,029,158 on May 12, 2015, which is a divisional
of U.S. patent application Ser. No. 12/062,808, filed Apr. 4,
2008, now abandoned, which claims priority under 35
U.S.C. §119(e) to U.S. provisional patent application No.
60/922,296, filed Apr. 6, 2007, now expired, the contents of
each of which are herein incorporated by reference in their
entirety.
GOVERNMENT RIGHTS
This invention was made with government support under
grant number NCC 9-58-317 awarded by National Space
Biomedical Research Institute through NASA. The govern-
ment has certain rights in this invention.
FIELD OF THE INVENTION
The present disclosure relates to fabricated microfluidic
devices that can be utilized as cell sensors and/or actuators.
In certain embodiments, the microfluidic device may be
used for labeling, sensing, differentiating, and/or sorting
targets, particularly cell populations.
BACKGROUND OF THE INVENTION
Standard cell sensors or actuators are generally based on
flow cytometry and employ one or a combination of elec-
trical impedance sensing, light scattering measurement, and
chemical or immunostaining followed by optical sensing.
For differentiation of blood cells by electrical impedance
sensing, red blood cells are removed by lysing in order to
reduce the blood volume. Lysing is generally done through
the use of saponin or surfactants. During the lysing process,
the leukocyte cell volume changes depending on cell type,
due to the leakage of cytoplasm contents and cell nucleus
shrinkage in varying amounts. Fujimoto, Sysmex J. Int. 9
(1990). Thus, normally 2-part (lymphocytes versus granu-
locytes) or even 3-part (lymphocytes, neutrophils, and other
leukocytes) differential can be achieved by simple electrical
impedance measurement of particle volume. Hughes-Jones,
et al., J. Clin. Pathol. 27; 623-625 (1974); Oberjat, et al., J.
Lab. Clin. Med. 76; 518 (1970); Vandilla, et al., Proc. Soc.
Exp. Biol. Med. 125; 367 (1967); Maeda, et al., Clin. Pathol.
27; 1117-1200 (1979); Maeda, et al., Clin. Pathol. 9; 555-
558 (1982). Combining direct current and alternating current
impedance, special acidic hemolysis in basophile channel
and alkali hemolysis in eosinophil channel, a 5-part leuko-
cyte differential can be achieved. Tatsumi, et al., Sysmex J.
Int. 9; 9-20 (1999).
Alternative optical methods are based on light scattering
and fluorescence staining of organelles, granules, and nuclei.
Generally, low-angle scattered light contains information on
cell size and high-angle scattered light can be used to probe
internal composition of the cell. To achieve 5-part differen-
tial, certain leukocyte populations, such as eosinophils,
require special stain to change its scattering characteristics
from other granulocytes, and basophils typically need to be
2
counted separately following the differential lysis of other
leukocytes. McKenzie, Clinical Laboratory Hematology,
Prentice Hall, 2004; Fujimoto, Sysmex J. Int. 9 (1999).
In general, conventional automated cell analyzers are
5 bulky, expensive, and mechanically complex, which restricts
their locations to hospitals or central laboratories. Conven-
tional cell analyzers require larger sample volumes and
generate more waste than the systems developed using
microdevices. Furthermore, for analysis of certain cell types,
to 
such as leukocytes, accuracy and speed of counting, differ-
entiation, and/or sorting is important for determining disease
state and treatment.
BRIEF DESCRIPTION OF THE SEVERAL
15 VIEWS OF THE DRAWINGS(S)
FIG. 1A shows the molecular structure of acridine orange.
FIG. 1B shows leukocyte staining results with acridine
20 orange.
FIG. 2 shows the top view of one embodiment of a novel
fabricated microfluidic apparatus.
FIG. 3 shows one embodiment of the optical system
setup.
25 FIG. 4A shows erythrocyte concentration in whole blood.
FIG. 4B shows leukocyte staining in whole blood with
acridine orange at a concentration of 100 ng/mL.
FIG. 4C shows leukocyte staining In whole blood with
acridine orange at a concentration of 1µg/mL.
30 FIG. 4D shows leukocyte staining in whole blood with
acridine orange at a concentration of 10 µg/mL.
FIG. 4E shows leukocyte staining In whole blood with
acridine orange at a concentration of 100 µg/mL.
FIG. 4F shows leukocyte staining in whole blood with
35 
acridine orange at a concentration of 1 mg/mL.
FIG. 5 shows fluorescent signal bleaching from a single
leukocyte in one embodiment.
FIG. 6A shows an image of background and a 5µm bead
40 with focused laser illumination flow taken by CCD camera
with long pass emission filter, according to one embodiment.
FIG. 6B shows an image of background and a 5µm bead
with laser illumination flow taken by CCD camera with long
pass emission filter, according to one embodiment.
45 FIG. 6C shows an image of background and a 5µm bead
with diffused laser illumination flow taken by CCD camera
with long pass emission filter, according to one embodiment.
FIG. 6D shows an image of background and the trace of
a 5µm bead with diffused laser illumination flow taken by
50 CCD camera with long pass emission filter, according to one
embodiment.
FIG. 7 shows a graph of detection of 5µm fluorescent
beads detection with photo-diode detector with long pass
emission filter.
55 FIG. 8A shows background image of focused laser beam
from video taken by CCD camera with long pass emission
filter, according to one embodiment.
FIG. 8B shows a signal from a leukocyte from diluted
whole blood testing from video taken by CCD camera with
60 long pass emission filter, according to one embodiment.
FIG. 9 shows the lime trace of amplified photodiode
signal of acridine orange stained undiluted whole blood with
green emission filter centered at 525 mu, and peaks labeled,
according to one embodiment.
65 FIG. 10 shows a histogram of signal intensity from
photodiode detector with green emission filter centered at
525 mu.
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FIG. 11 shows a histogram of signal intensity from
photodiode detector with red emission filter centered at 650
run.
FIG. 12A shows an illustration of a handheld defection
box instrument according to one embodiment.
FIG. 12B shows an assembled detection box instrument
according to one embodiment.
FIG. 13A shows the top view of an apparatus according
to one particular embodiment.
FIG. 13B shows the top view of an apparatus according
to one particular embodiment.
SUMMARY OF THE INVENTION
Certain embodiments disclosed herein include a micro-
fluidic apparatus comprising a substrate having a first chan-
nel having a defined physical feature, wherein said first
channel is in fluid communication with at least one inlet for
receiving a fluid, wherein said first channel leads to a
restrictive access, and wherein said first channel is in fluid
communication with a second channel having a defined
physical feature, wherein said second channel is in fluid
communication with at least one fluid flow outlet; and a fluid
biological sample. In certain embodiments, said defined
physical feature is a depression or protrusion. In particular
embodiments, said fluid biological sample comprises blood.
In certain embodiments, the microfluidic apparatus further
comprises a detection zone, and/or a filter array, each in fluid
communication with said channel and said fluid flow outlet.
Amicrofluidic apparatus comprising a substrate having at
least one first channel having a defined physical feature; at
least one first inlet formed in said first channel for receiving
a first fluid; wherein said first channel is in fluid communi-
cation with a bifurcated channel, wherein said bifurcated
channel is in fluid communication with a third channel
detection zone; at least one second inlet for receiving a
second fluid, wherein said second inlet is in fluid commu-
nication with a branched channel; a filter structure in fluid
communication with a reservoir, wherein said reservoir is in
fluid communication with said third channel detection zone;
at least one fluid flow outlet formed In said third channel;
and a fluid sample; wherein the ratio of the cross-sectional
area of said second channel compared to the cross-sectional
area of said first channel is 1:10. In certain embodiments, the
defined physical feature is a depression or a protrusion.
In certain embodiments, said filter structure comprises a
filter array, said first fluid comprises sheath fluid and said
second fluid comprises blood.
Certain embodiments disclosed herein relate to a detec-
tion system comprising a microfluidic apparatus and further
comprising a light source; a lens assembly; a filter assembly;
and an image capture device. In some embodiments, the
detection system further comprises at least one display unit
or at least one recording unit. In certain particular embodi-
ments, said excitation source comprises a laser, particularly
an argon laser. In particular embodiments, said filter assem-
bly comprises an excitation filter, and at least one emission
filter. In certain embodiments, said filter assembly further
comprises at least one aperture and at least one neutral
density filter. In particular embodiments, said filter assembly
further comprises at least one glass polarizer.
In certain embodiments, the lens assembly of the detec-
tion system comprises at least one condenser lens, at least
one objective lens, and at least one beamsplitter. In particu-
lar embodiments, said image capture device comprises at
least one CCD camera, CMOS device, photodiode, or pho-
tomultiplier tube. In certain embodiments, said filter assem-
4
bly comprises at least two emission filters and said image
capture device comprises at least one photomultiplier tube.
In certain embodiments, said display unit comprises a com-
puter and said recording unit comprises an oscilloscope. In
5 particular embodiments, said excitation source comprises an
argon laser; said lens assembly comprises a condenser lens,
an objective lens, and a beamsplitter; said filter assembly
comprises an excitation filter, a pinhole aperture and a
neutral density filter, and at least one emission filter; said
10 image capture device comprises a CCD camera and a
photodiode, and said display unit comprises a personal
computer, and further comprising an amplifier.
In particular embodiments, said excitation source of the
15 detection system comprises an argon laser; said lens assem-
bly comprises a condenser lens, an objective lens, and a
beamsplitter, said filter assembly comprises an excitation
filter, at least one emission filter; said image capture device
comprises a photomultiplier tube, and said display unit
20 comprises a personal computer.
Other embodiments disclosed herein relate to a method
for identifying a target comprising providing a fluid sample
to at least one microfluidic apparatus, wherein said fluid
sample contains at least one dye; providing an excitation
25 source to induce at least one fluorescent signal in a target;
defecting the fluorescent signal using a sensor in the appa-
ratus; and identifying the target based in part on the analysis
of the fluorescent signal. In certain embodiments, said target
is selected from the group consisting of: cells, organelles,
30 nuclei, granules, DNA, and RNA. In other embodiments,
said target comprises a cell selected from the group consist-
ing of a monocyte, a granulocyte, a macrophage, a neutro-
phil, an eosinophil, a basophil, or other leukocyte. In specific
embodiments, said target comprises a leukocyte and said dye
35 comprises acridine orange. Particular embodiments of the
method further comprising counting or sorting the target in
the sample by analysis of the fluorescent signal. In certain
embodiments, said fluid sample comprises blood.
40 DETAILED DESCRIPTION OF THE
INVENTION
The present disclosure relates to fabricated microfluidic
devices that can be utilized as cell sensors and/or actuators.
45 In certain embodiments, the microfluidic device may be
used for labeling, sensing, differentiating, and/or sorting cell
populations.
Microfluidic cell sensors and actuators can provide cell
sensing and counting for a more accurate outcome and a
50 lower cost. Particle counting (including bead, erythrocyte,
and cultured cell) has been demonstrated, for example, by
electrical impedance sensing, light scattering detection, and
fluorescent sensing. Gawad, et al. Lab Chip 1; 76 (2001);
Lee, et al. Proceedings of the 18th IEEE International
55 Conference on Micro Electro Mechanical Systems (MEMS)
678-681 (2005); Satake et al. Sens. Actuators B: Chem. 83;
77 (2002); Morgan, et al. Curr. Appl. Phys. 6, 367-370
(2006); Lee et al., J. Micromech. Microeng. 15; 447-454
(2005); Altendorf, et al. Proceedings of the International
60 Conference on Solid State Sensors and Actuators (Trans-
ducers '97) v. 1, p. 531, Chicago, Ill. (1997); Holmes et al.,
Biosens. Bioelectron. 21; 1621-1630 (2006); Yang et al.,
Meas. Sci. Technol. 17; 2001-2009 (2006); Simonnet et al.,
Anal. Chem. 78; 5653-5663 (2006); Niehren, et al., Anal.
65 Chem. 67; 2666-2671 (1995).
In the area of optical sensing, microfabrication has
allowed development of microdevices to replace glass cap-
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illary-based flow chambers, and to integrate compact optics
and provide on-chip sample transport.
Cell sensing and counting, particularly of leukocytes, is
cumbersome due in part to the cell population numbers. For
leukocyte differential in microdevices based on optical sens- 5
ing, a V-groove micro-channel was fabricated by anisotropic
wet etching of a silicon substrate and 3-part leukocyte
differential was demonstrated for diluted blood without
sheath flow by two-parameter light scattering. Altendorf,
Proceedings of the Int'l Conference on Solid State Sensors 10
and Actuators, v. 1, p. 531 (1997).
However, until the instant embodied disclosure, it was
necessary to dilute cell samples for cell sensors and actua-
tors for many reasons. One reason dilution has been neces-
sary is in order to prevent the coincidence effect in which 15
multiple cells appear in the defection zone simultaneously.
In human blood, the ratio of erythrocytes, or red blood cells,
to leukocytes is on the order of about a thousand to one, a
dilution factor of from about one hundred to several tens of
thousands is typically required to avoid erythrocyte inter- 20
ference for electrical impedance or light scattering defec-
tion. Furthermore, for counting leukocytes in samples where
leukocytes are specifically fluorescently labeled, a dilution
of at least ten times is usually required. Sheenan and Storey,
J. Pathol. Bacteriol. 59; 336 (1947); Kass, J. Clin. Pathol. 25
76; 810-12 (1981); Weigl et al., Biomed. Microdeu 3;
267-274 (2001);
Dilution is also often required in order to avoid clogging
sample chambers, and also In order to remove erythrocytes
that are lysed prior to running the sample, particularly for 30
electrical impedance or light scattering detection. Some of
these protocols also require an additional fixation buffer.
Dyes
In the present disclosure, a dye, such as Acridine orange
(3,6-dimethylamineoacridine, FIG. 1), can be used to dif- 35
ferentiate a target, such as cells, organelles, granules, nuclei,
molecules (including double or single stranded nucleic
acids, such as DNA, or RNA, chromosomes, and also
including synthetic forms). In one particular embodiment,
leukocytes may be detected, counted, or sorted without need 40
for lysing erythrocytes or fixing the cell sample. Certain
dyes, such as Acridine orange, are also desirable due to the
fast diffusion into cells, easy commercial availability, and
excitation and emission wavelength compatibility with com-
mon light sources (i.e. argon laser and other broad spectrum 45
light sources in visible range) and optical filters. Kosenow,
Acta Haematol. 7, 217 (1952); Schiffer, Blood, 19, 200
(1962): Jackson, Blood, 17, 643 (1961); Hallermann et al.,
Verh Deutsch Ges Inn Med. 70, 217 (1964).
Acridine orange is a pH-sensitive fluorescent cationic dye 50
that binds to double-stranded DNA by electrostatic attraction
and intercalation of the Acridine orange between base pairs.
Upon binding, the excitation maximum becomes 502 mu
and the emission maximum becomes 525 mu (green). Acri-
dine orange also binds to RNA and single-stranded DNA, 55
with a shifted excitation maximum of 460 mu and an
emission maximum of 650 nm (red). Adams and Kamentsky,
Acta Cytol. 15, 289 (1971); Adams and Kamentsky Acta
Cytol. 18, 389-91 (1974); Steinkam et al., Acta Cytol. 17,
113-17 (1973). Acridine orange is also desirable in that it is 60
hydrophobic in neutral pH, and can easily diffuse through
the cell membrane and cell nuclear membrane to bind to
RNA and DNA. In living cells, Acridine orange is proto-
nated in the acidic environment of lysosomes, which makes
it cationic and prevents the dye from leaking out of lysosome 65
membranes. Moriyama et al., J. Biochem. 92; 1333-36
(1982). When Acridine orange is used for leukocyte analy-
T
sis, the cell nucleus is stained green with slightly mixed red,
a result of double-stranded DNA and single-stranded RNA,
while the cell cytoplasm is stained red due to the RNA and
lysosomes. Thus, leukocyte counting can be achieved easily
by using the strong signal from the green fluorescent chan-
nel. Leukocyte differentiation can be achieved by analyzing
the signal from the red fluorescence channel.
For fresh-stained leukocytes, a 3-part differential (lym-
phocytes, monocytes, and granulocytes) can be achieved by
studying the red fluorescent signal of an Acridine orange
stained diluted blood sample, whereas a 5-part differential
leukocytes (lymphocytes, monocytes, neutrophils, eosino-
phils, and basophils) has been demonstrated with hypotonic
dilution and fresh Acridine orange-stained leukocyte
samples. Adams and Kamentsky, Acta Cytol. 15, 289 (1971);
Adams and Kamentsky, Acta Cytol. 18, 389-391 (1974);
Steinkam et al., Acta Cytol. 17, 113-17 (1973).
Other dyes can be utilized with certain embodiments
described in the instant disclosure, such as ethidium bro-
mide, three-dye combinations (ethidium bromide, brilliant
sulfaflavine, and stilbene disulfonic acid derivative);
oxazine dyes, basic orange 21, and a polymethine dye.
Shapiro, et al., J. Histochem. Cytochem. 24, 396-411 (1976);
Shapiro, et al., J. Histochem. Cytochem. 25, 836-844 (1977);
U.S. Pat. No. 4,376,820; U.S. Pat. No. 4,882,284; Tibbe, et
al., Nat. Biotechnol. 17, 1210-1213 (1999); U.S. Pat. No.
4,400,370; Kass, J. Histochem. Cytochem. 36, 711-715
(1988).
Apparatus
One embodiment of the instant disclosure relates to a
device or apparatus for cell counting and/or differentiating.
In particular embodiments, the device or apparatus com-
prises a substrate formed from a material, such as silicon,
glass, plastic, metal, or other material. One particular
embodiment of the instant disclosure was fabricated using
soft lithography. Quake, Science 290, 1536-40 (2000). Other
photolithographic or etching techniques could also be used,
according to specific embodiments.
One embodiment of the device was microfabricated using
two parts of PDMS (polydimethylsiloxane) (Sylgard 184,
Dow Corning, MI, USA) mixed vigorously in 10:1 ratio.
After degassing in vacuum for about 30 minutes, the mixture
was poured onto DRIE-etched silicon mold, that had been
pretreated with HMDS (hexamethyldisilazane) for easy
separation after baking. The molds were baked at 80° C. for
30 minutes. The hardened PDMS was separated from the
silicon mold, and PDMS sheet was cut into pieces and
fluidic access holes were punctured on each piece with a
Luer stub adapter (Becton Dickinson, NJ, USA). Each
PDMS piece was carefully placed on a cleaned glass slide
and baked overnight at 80° C. In some cases, oxygen plasma
treatment (300 m Torr, 25 W, 30 s) was used for PDMS and
glass slides in order to improve adhesion between them,
particularly with devices that were intended to be reused.
Bhattacharya et al., J. Microelectromechan. Syst. 14, 590-97
(2005).
In one particular embodiment, the channel structure was
molded on a 1 cmxI cm PDMS block, with the thickness of
the PDMS block at less than 3 mm. In one particular
embodiment the channel depth was 16 µm in order to
accommodate large leukocyte sizes.
One exemplary embodiment of the device is shown in
FIG. 2. For this particular embodiment, a first fluid flow Inlet
200 allows for deposition of, for example sheath flow fluid,
and is in fluid communication with a bifurcated channel with
a first channel arm 260 and a second channel arm 270 that
both converge at a junction of a reservoir 290 and the
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detection zone 240. In this particular embodiment, the
apparatus further comprises a second fluid flow inlet 210
that allows for deposition of, for example, a sample fluid,
such as blood, that is in fluid communication with a filter
array structure 230, by way of a branched sample flow zone 5
channel 220 and a fluid flow outlet 250. In this particular
exemplary embodiment, 2-D hydrodynamic focusing was
adopted to control the particle position of the cell sample in
the detection zone 240. According to the embodiment shown
in FIG. 2, the ratio of cross-sectional area of sheath flow to io
core sample flow was 10:1, and the channel width of the
defection zone 240 was 50 µm, with the width of the focused
sample flow preferably 5µm or less. In particular embodi-
ments, the channels comprise a physical feature, such as a
depression or a protrusion. 15
One other exemplary embodiment of the device is shown
in FIG. 13A. For this particular embodiment the fluid flow
inlet 1340 allows for deposition of a sample fluid, such as a
biological sample, or other fluid sample containing a target.
In one particular embodiment, the biological sample 20
includes a cell sample, such as blood. In this exemplary
embodiment, the fluid inlet is in fluid communication with
a first channel 1330 which contains a restrictive access 1320
that is juxtaposed to a second channel 1310 which comprises
the detection zone which is also in fluid communication with 25
the fluid flow outlet 1300. In certain embodiments, the
height of the first and/or second channels is approximately
5 µm, approximately 8µm, approximately 10 µm, approxi-
mately 12 µm, approximately 15 µm, approximately 20 µm,
approximately 25 µm, approximately 30 µm, approximately 30
35 µm, approximately 40 µm, or any value therebetween. In
certain embodiments, the width of the second channel is
approximately 5µm, 10 µm, approximately 15 µm, approxi-
mately 20 µm, approximately 25 µm, approximately 30 µm,
approximately 35 µm, approximately 40 µm, approximately 35
45 µm, approximately 50 µm, or any value therebetween. In
the exemplary embodiment shown in FIG. 13A, the second
channel width was approximately 20 µm in size.
One other exemplary embodiment of the device is shown
in FIG. 13B. For this particular embodiment, the fluid flow 40
inlet 1440 allows for deposition of a sample fluid, such as a
biological sample, or other fluid sample containing a target.
In one particular embodiment, the biological sample
includes a cell sample, such as blood. In this exemplary
embodiment, the fluid inlet is in fluid communication with 45
a first channel 1430 which contains a restrictive access 1420
that is juxtaposed to a second channel 1410 which comprises
the detection zone which is also in fluid communication with
the fluid flow outlet 1400. In certain embodiments, the
height of the first and/or second channels is approximately 50
5 µm, approximately 8µm, approximately 10 µm, approxi-
mately 12 µm, approximately 15 µm, approximately 20 µm,
approximately 25 µm, approximately 30 µm, approximately
35 µm, approximately 40 µm, or any value therebetween. In
certain embodiments, the width of the second channel is 55
approximately 5µm, 10 µm, approximately 15 µm, approxi-
mately 20 µm, approximately 25 µm, approximately 30 µm,
approximately 35 µm, approximately 40 µm, approximately
45 µm, approximately 50 µm, or any value therebetween. In
the exemplary embodiment shown in FIG. 1313, the second 60
channel width was approximately 30 µm in size.
Certain embodiments of the device use a focused laser
source for illumination, since cell focusing in the detection
zone 240 is highly desirable. However, other embodiments
included in the present disclosure use a more uniform 65
diffused light source and a slit aperture. Such embodiments
utilize straight channel geometry without cell focusing. In
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one embodiment, the channel length of the detection zone
240 is 1000 µm. Afilter structure 230 upstream of the sample
flow zone 220 may also be included in certain embodiments,
which filtered out contaminants, including erythrocyte rou-
leaux, and other large particle aggregates to prevent clog-
ging in the detection zone 240. In certain embodiments, the
size of the rectangular pillar structure components of the
filter structure 230 was 200 µmx40 µm. The spacing
between the pillars in each of the three rows was 40 µm, 30
µm, and 20 µm respectively, which allows for even the
largest leukocytes to pass through the filter region 230.
System
The optical system was set up on an optical bench as
shown in FIG. 3 (transmitted laser-induced fluorescent
detection system or LIF). In one particular embodiment, the
system setup comprises an excitation or laser source 300, a
lens assembly 340, the microfluidic apparatus 350, an
optional additional lens assembly 360, a filter assembly 320,
330, and an image capture device 390, 395. In certain
embodiments, one or more emission filters comprise, the
filter assemblies 320, 330. In certain embodiments, the
image capture device 395 comprises a charge coupled
device (CCD) camera, a complementary metal-oxide-semi-
conductor (CMOS) device, or a photomultiplier tube (PMT)
device. In particular embodiments, the image capture device
395 may be coupled to communicate with a display unit or
computing device 396, such as a personal computer. One of
skill in the art would recognize that multiple and various
computer software programs are available that allow for
integration, compilation, analysis, reconfiguration, and other
manipulation of data received from the system, particularly
by way of the computing device 396.
In one particular exemplary embodiment, an argon laser
(National Laser NLC210BL, 483 mu, and 15-30 mW adjust-
able, Salt take City, Utah, USA) is used as the excitation
source. An aperture 310 of 50 µm diameter is put in front of
the laser output to facilitate the alignment process and lower
the illumination intensity. In certain embodiments, art
optional laser-line bandpass filter (bandwidth equal to about
1.9 nm with a central wavelength of 488 mu) is used to
further purify the laser source. In certain other embodiments,
an optional neutral density filter (NDF) is used to attenuate
laser excitation. Alternatively, the pinhole and NDF are
replaced by two linear glass polarizers (Edmond Optics
TECH SPEC, Barrington N.7., USA) so that the Illumination
level on the device can be easily adjusted.
In one particular embodiment, a long-working-distance
microscope objective (USMCO M Plan Apo, 10x, 0.28 NA,
Dayton, Nev., USA) is used as a condenser lens 340.
Another long-working-distance microscope objective
(Bausch & Lomb, 50x, 0.45 NA, Rochester, N.Y., USA) is
used as an objective lens 360. In the same embodiment, three
emission filters 320 are used in one particular test: 488 mn
long pass filter (Chroma H1500 LP, transition width>4.9 mu,
edge steepness=2.5 mu, Rockingham, Vt., USA), a green
bandpass filter with central wavelength 525 mn and a
bandwidth 50 mn (Chroma D525_50 m), and a red bandpass
filter with central wavelength 650 mn and bandwidth 50 mn
(Chroma D650_50 m). A broadband non-polarizing hybrid
cube beamsplitter 370 (Newport 05BC17MB.1, 400-700
mu, R/T=45%/45%, Irvine, Calif., USA) is used to direct
light to the photodiode detector 380 and CCD camera
simultaneously.
The signal is electrically amplified and detected either
with a silicon photodiode receiver module 390 (Electro-
Optical Systems, UVS-025-H, Phoenixville, Pa., USA) or a
photon multiplier tube (PMT, Hamamatsu H5784-20,
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Japan). The voltage signal is sent to a deep memory oscil-
loscope (HP 54645A, Palo Alto, Calif., USA). When the
buffer in the oscilloscope is full, the data can be loaded to a
computer and analyzed with a Matlab peak-detection pro-
gram. Video may be taken with an analog CCD camera 5
(Hitachi KP-D20B, Japan) at 30 frames per second and then
converted to digital format and stored in a computer 396.
Other imaging capture devices 395, such as CMOS, PMT, or
still other devices may also be used with particular embodi-
ments described herein. In certain exemplary test runs, the io
system set up utilizing a photodiode detector and PMT are
more sensitive than the CCD camera and have a faster time
response. During one exemplary test run, the optical system
was first roughly aligned on a dummy device with the aid of
images from CCD camera. A 10 µm diameter illumination 15
spot on the detection zone is easily achieved with proper
alignment.
As shown in FIG. 12A and FIG. 12B, the instant apparatus
may be incorporated into a hand-held unit comprising a laser
source (such as a laser emitting diode or LED 120), at least 20
one lens 190, at least one filter assembly with optional
beamsplitter 195, a microfluidic apparatus as described
herein on a microchip or other substrate 185, an input/output
port 130, at least one image capture device 100, 110, which
may be a photomultiplier tube. In certain embodiments, the 25
hand-held unit may be assembled and enclosed by an outer
casing or casings 160, 180, and rivets or bolts 140, 160.
Cell Detection
One aspect of the instant disclosure relates to methods of
counting and/or differentiating cells, particularly leukocytes, 30
from undiluted cell samples, such as human or other animal
blood, by utilizing microfabricated devices. In one exem-
plary embodiment, cell detection was conducted utilizing
Acridine orange and fresh whole human blood.
In one exemplary embodiment, fresh human blood was 35
obtained from healthy donors and used within 3 days of
collection. EDTA was added to the blood samples in order
to prevent coagulation. For Acridine orange staining, the
stock solution was added to obtain a final dye-concentration
of 10 µg/mL in Ficoll-Paque Plus. Ficoll-Paque Plus was 40
also used as the sheath flow solution. Fluorescent polysty-
rene beads (5 µm green fluorescent beads) were purchased
from Duke Scientific Corporations, Fremont, Calif., USA.
Cell nucleus stain Acridine orange was obtained from
Molecular Probes, Eugene, Oreg., USA, and dissolved in 45
water to achieve a 10 mg/mL stock solution. Blood diluent
Ficoll-Paque Plus was purchased from Amersham Biosci-
ences, Sweden. Phosphate buffered saline (10xPBS) was
obtained from Ambion (9625), Austin, Tex., USA.
Staining results were observed under a fluorescent micro- 50
scope (Nikon E800, Japan) with a triple band filter block
DAPI-FITC-TRITC, which has excitation filter wavelengths
of 385-400 mu, 475-490 mu, and 545-565 mu, and emission
filter wavelengths of 450-465 mu, 505-535 nm and 580-620
mu. Images were taken with a cooled CCD camera (RT-KE 55
color 3-shot, Diagnostic Instruments, Sterling Heights,
Mich., USA). Rough count of leukocytes was made with a
hemactyometer (Hausser Scientific, Horsham, Pa., USA).
When necessary, blood or fluorescent beads were diluted
with Ficoll-Paque Plus (specific gravity 1.077 g/mL) to 60
match the specific gravity of the solvent to leukocytes. All
fluids were pumped into the devices using syringe pumps
(Harvard Apparatus Pico Plus, Holliston, Mass., USA).
In this particular embodiment, an analog CCD camera
was used for video recording at a matched camera frame rate 65
of 3 nL/min sample flow rate and 30 nL/min sheath flow
rate. For photodiode detection, a 0.1 µL/minute sample flow
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rate and a 1µL/minute sheath flow rate were used. A 1
µL/minute sample flow and a 10µL/minute sheath flow were
used with the photon multiplier tube instrument.
In order to achieve a high signal-to-noise ratio, the
maximal concentration for cell staining was established
using routine methods in the art. Adams and Kamentsky,
Acta Cytol. 15; 289 (1971). As shown in FIG. 4, whole blood
samples were analyzed with different Acridine orange con-
centrations. The optimal concentration for leukocyte stain-
ing was determined to be approximately in the range of 1
µg/mL. In the particular exemplary embodiment utilized in
FIG. 4, the distance between the coverslip and the grid
surface was approximately 100 µm. As can be seen in FIG.
4A, an abundance of erythrocytes were present under the
field of view, yet these cells did not interfere with the
fluorescent signal from the leukocytes, as shown in FIG.
4B-F.
As can be seen in FIG. 5, the exemplary embodiment
utilized in cell detection did not experience any significant
photobleaching. The signal was fitted as a first-order expo-
nential decay with time constant of 6.4+/-0.7 seconds. Two
more tests confirmed that the photobleaching time constant
for one particular embodiment was between 1 second and 10
seconds. The photobleaching time constant for one particu-
lar embodiment was characterized by filling the device with
Acridine orange-stained whole blood. The channel was
scanned by the laser spot and the illumination was set to be
the same as that used in testing. The entire process was
recorded with a CCD camera. Whenever a fluorescing
leukocyte was observed with fluorescent emission clearly
distinct from the background, we stopped moving the laser
spot and waited until the leukocyte was photobleached to
background level. The images were extracted from the
video, converted to 8-bit gray scale images, and analyzed
with a Matlab program. The data was fitted to a single
time-constant exponential decay.
Additionally, green fluorescent beads were tested at a
concentration of about 2x103/µL, as observed by CCD
camera, and shown in FIG. 6. Sample flow rate was set at
about 3 nL/min, and sheath flow was about 30 nL/min. In
one exemplary test run, a hydrodynamic focused laser beam,
as shown in FIG. 6A, created an enlarged light circle as
shown in FIG. 6B. Only a single bead normally appeared in
each image. With diffused laser illumination, as shown in
FIG. 6C, the trace of the bead could be identified, as shown
in FIG. 6D. Hydrodynamic focusing limits the cross-sec-
tional area of the defection zone without shrinking the
channel diameter, thus the signal-to-noise ratio may be
improved without increasing the risk of clogging the chan-
nel. Also, the reduction of the cross-section of the core flow
reduces the coincidence effect. Finally, enclosing the core
sample flow with sheath flow minimizes fluorescent dye
absorption in the device walls, thus reducing background
noise. As indicated in FIG. 7, bead signals from the photo-
diode detector could easily be identified.
As shown in FIG. 8, using both red and green emission
filters, images extracted from video taken by the CCD
camera show the signal identified from a leukocyte stained
with Acridine orange, as well as the signal obtained from the
fluorescent control bead. For photodiode detection, the
expected leukocyte detection rate would average about 4-11
cells per second for a normal individual.
In one exemplary embodiment, a time trace over 50
seconds of an undiluted blood sample stained with Acridine
orange using a green emission filter, and a throughput of up
to about 1000 leukocytes per second was attained. Maxima
signal Intensity (peak height as in FIG. 9) from the green
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fluorescent channel with 525 mu emission filter was studied
by plotting its histogram, as shown in FIG. 10. As expected,
the lower-intensity portion Is likely contributed mainly by
lymphocytes, while the higher-intensity portion is likely
mainly from monocytes, with the center-region is likely
mostly from granulocytes. Steinkam et al., Acta Cytol. 17;
113-117 (1973).
In one exemplary embodiment, a time trace over 50
seconds of an undiluted blood sample stained with Acridine
orange using a red fluorescent channel with 650 mu emis-
sion filter was conducted. As shown in FIG. 11, two peaks
were identified. The lower intensity is dominated by lym-
phocytes and the higher-intensity peak is largely monocytes
and granulocytes. The time between the start of staining the
cells to photodiode recording was typically greater than 15
minutes.
In both exemplary studies, the maximal throughput was
about 1000 leukocytes per second utilizing one embodiment
of the PMT detector. By using undiluted blood, minimal
sample volume was maintained, which increases the
throughput. Since sample throughput is proportional to
volume flow rate, but is limited by the maximal pumping
rate and response time of the sensing system, a 3 nL/minute
core flow rate was used with the CCD camera defection.
Under this flow rate, a typical leukocyte traveled through the
detection zone in approximately 30 milliseconds, which
roughly equals the CCD frame acquisition time.
Flow rates for varying embodiments may be suitable for
a range from approximately 1 nL/minute, approximately 2
nL/minute, approximately 3 nL/minute, approximately 4
nL/minute, approximately 5 nL/minute, approximately 6
nL/minute, approximately 7 nL/minute, approximately 8
nL/minute, approximately 9 nL/minute, approximately 10
nL/minute, approximately 20 nL/minute, approximately 30
nL/minute, approximately 40 nL/minute, approximately 50
nL/minute, approximately 60 nL/minute, approximately 70
nL/minute, approximately 80 nL/minute, approximately 90
nL/minute, approximately 100 nL/minute, approximately
110 nL/minute, approximately 120 nL/minute, approxi-
mately 130 nL/minute, approximately 140 nL/minute,
approximately 150 nL/minute, or any value therebetween
for photodiode detection. Likewise, for PMT defection, flow
rates for varying embodiments may be suitable for a range
from approximately 200 nL/minute, approximately 300
nL/minute, approximately 400 nL/minute, approximately
500 nL/minute, approximately 600 nL/minute, approxi-
mately 700 nL/minute, approximately 800 nL/minute,
approximately 900 nL/minute, approximately 1µL/minute,
approximately 2µL/minute, approximately 3µL/minute,
approximately 4µL/minute, approximately 5µL/minute, or
any value therebetween.
In one exemplary embodiment, the time response of the
photodiode receiver module under low sensitivity setting
was 0.16 milliseconds, and 0.6 milliseconds under high
sensitivity, while the time response of the PMT detector in
one exemplary run was about 16 microseconds.
Furthermore, by decreasing the cross-sectional area, the
linear flow velocity of the core flow is increased, which
requires faster sensing, and reduces the coincidence effect by
increasing the average distance between cells in the detec-
tion zone.
Thus, by utilizing particular embodiments disclosed
herein relating to a microfluidic device, leukocyte sensing,
counting, and sorting can be achieved one-by-one in a micro
flow cytometer system. Furthermore, dense cell suspensions,
such as whole, undiluted blood may be utilized in certain
embodiments described herein, which provides for reduced
12
sample and waste volume, reduced processing time, and
completely eliminates on-chip mixing and buffer storage. In
particular aspects, leukocytes can be sensed one-by-one in a
micro flow cytometer system.
5 As described herein, certain embodiments of the device
can be implemented in various sizes and conformations,
including but not limited to a bench-top device, a handheld
device (such as is shown in FIG. 12), an implantable device,
a nanotechnology device, or other size or conformation. In
io the smaller exemplary conformations, high-illumination
LED is used for excitation and a minipump is used to
manipulate the sample in suction mode, while fluorescent
signals from green and red channels can be detected simul-
taneously.
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INCORPORATION BY REFERENCE
All of the above U.S. patents, U.S. patent application
publications, U.S. patent applications, foreign patents, for-
20 eign patent applications and non-patent publications referred
to in this specification and/or listed in the Application Data
Sheet, are incorporated herein by reference, in their entirety.
The invention claimed is:
1. A method for analyzing cells, the method comprising:
25 (a) introducing a fluid sample comprising fluorescently
labeled cells and fluorescently labeled control beads to
an inlet of a first microfluidic channel, wherein the
fluorescently labeled cells are labeled with a fluoro-
phore different than a fluorophore label of the control
30 beads;
(b) flowing the fluid sample from the inlet of the first
microfluidic channel to an outlet of a second microflu-
idic channel, wherein an outlet of the first microfluidic
channel is physically and fluidically coupled to an inlet
35 of the second microfluidic channel and wherein the
flow of the fluid sample is aided with a pump;
(c) exciting the fluorophores of the fluorescently labeled
cells and of the fluorescently labeled control beads
using an excitation source;
40 (d) detecting fluorescence of the fluorescently labeled
cells and fluorescence of the fluorescently labeled con-
trol beads as they pass through a detection zone within
the second microfluidic channel, wherein the detection
is performed on individual cells;
45 (e) analyzing the detected fluorescence of the fluores-
cently labeled cells and fluorescence of the fluores-
cently labeled control beads using a computer software
inscribed on a computing device; and
(f) providing a result concerning one or more properties of
50 the cells being analyzed.
2. The method of claim 1, wherein the cells are leuko-
cytes.
3. The method of claim 1, wherein the fluid sample is a
treated blood sample.
55 4. The method of claim 1, wherein the second microfluidic
channel has fixed dimensions.
5. The method of claim 4, wherein the fixed dimensions
are of approximately 40 microns by approximately 50
microns.
60 6. The method of claim 1, wherein the first channel and
the second channel are obstacle-free.
7. The method of claim 1, wherein the flowing of the fluid
sample from the inlet of the first microfluidic channel to the
outlet of the second microfluidic channel increases a core
65 flow rate of the fluid sample to form an increased flow rate.
8. The method of claim 1, wherein the method further
comprises identifying the fluorescently labeled cells.
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9. The method of claim 1, wherein the method further
comprises sorting the fluorescently labeled cells.
10. The method of claim 1, wherein the method further
comprises counting the fluorescently labeled cells.
11. The method of claim 1, further comprising video 5
recording a measurement on a recording unit.
12. The method of claim 1, wherein the method can detect
cells at a rate of up to about 1000 cells per second.
13. The method of claim 1, wherein the excitation source
is a laser or a LED. 10
14. The method of claim 1, wherein the excitation source
comprises a lens assembly.
15. The method of claim 1, further comprising manipu-
lating the detected fluorescence using a computer software
program. 15
16. The method of claim 15, further comprising display-
ing a result of the manipulation on a display unit.
17. The method of claim 1, wherein the fluorescently
labeled beads are polymeric beads.
18. The method of claim 1, wherein the fluorescently 20
labeled beads are polystyrene beads.
19. The method of claim 1, wherein the step of detecting
fluorescence comprises using an image capture device.
20. The method of claim 1, wherein flowing the fluid
sample comprises pumping the fluid sample through a 25
microfluidic device with the pump.
21. The method of claim 1, wherein the fluid sample does
not comprise a sheath fluid.
22. The method of claim 1, wherein the fluid sample is an
undiluted blood sample. 30
